# Ocular Therapeutix, Inc: financial statements, quarterly

OCUL · Nasdaq · CIK 1393434 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/ocul.md) · [Financials](/companies/ocul/financials.md) · [Filings](/companies/ocul/filings.md) · [Insiders](/companies/ocul/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/ocul/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [15.1](/filings/0001558370-24-015613.md) | [14.8 d](/filings/0001104659-26-010664.md) | [14.8](/filings/0001558370-25-006225.md) | [16.4](/filings/0001558370-25-010177.md) | [15.4](/filings/0001104659-25-105919.md) | [17.1 d](/filings/0001104659-26-010664.md) | [10.7](/filings/0001104659-26-055256.md) | [13.5](/filings/0001104659-26-089450.md) | [14.5](/filings/0001104659-25-105919.md) | [13.3 d](/filings/0001104659-26-010664.md) | [10.8](/filings/0001104659-26-055256.md) | [13.5](/filings/0001104659-26-089450.md) |
| Cost of revenue | $m | [1.4](/filings/0001558370-24-015613.md) | [1.4 d](/filings/0001104659-26-010664.md) | [1.3](/filings/0001558370-25-006225.md) | [1.5](/filings/0001558370-25-010177.md) | [1.6](/filings/0001104659-25-105919.md) | [1.2 d](/filings/0001104659-26-010664.md) | [1.3](/filings/0001104659-26-055256.md) | [1.9](/filings/0001104659-26-089450.md) | [1.8](/filings/0001104659-25-105919.md) | [1.6 d](/filings/0001104659-26-010664.md) | [1.3](/filings/0001104659-26-055256.md) | [2.0](/filings/0001104659-26-089450.md) |
| Research and development | $m | [15.0](/filings/0001558370-24-015613.md) | [16.2 d](/filings/0001104659-26-010664.md) | [20.7](/filings/0001558370-25-006225.md) | [28.9](/filings/0001558370-25-010177.md) | [37.1](/filings/0001104659-25-105919.md) | [41.0 d](/filings/0001104659-26-010664.md) | [42.9](/filings/0001104659-26-055256.md) | [51.1](/filings/0001104659-26-089450.md) | [52.4](/filings/0001104659-25-105919.md) | [50.8 d](/filings/0001104659-26-010664.md) | [66.2](/filings/0001104659-26-055256.md) | [54.1](/filings/0001104659-26-089450.md) |
| Operating income | $m | [(19.2)](/filings/0001558370-24-015613.md) | [(20.1) d](/filings/0001104659-26-010664.md) | [(31.6)](/filings/0001558370-25-006225.md) | [(43.6)](/filings/0001558370-25-010177.md) | [(46.0)](/filings/0001104659-25-105919.md) | [(50.6) d](/filings/0001104659-26-010664.md) | [(63.9)](/filings/0001104659-26-055256.md) | [(67.6)](/filings/0001104659-26-089450.md) | [(68.7)](/filings/0001104659-25-105919.md) | [(69.8) d](/filings/0001104659-26-010664.md) | [(93.3)](/filings/0001104659-26-055256.md) | [(82.1)](/filings/0001104659-26-089450.md) |
| Interest expense | $m | [3.4](/filings/0001558370-23-017989.md) | [4.2 d](/filings/0001558370-24-002902.md) | [4.1](/filings/0001558370-24-007065.md) | [3.2](/filings/0001558370-25-010177.md) | [3.2](/filings/0001104659-25-105919.md) | [3.1 d](/filings/0001104659-26-010664.md) | [3.0](/filings/0001104659-26-055256.md) | [3.0](/filings/0001104659-26-089450.md) | [3.0](/filings/0001104659-25-105919.md) | [2.8 d](/filings/0001104659-26-010664.md) | [2.8](/filings/0001104659-26-055256.md) | [2.8](/filings/0001104659-26-089450.md) |
| Net income | $m | [(0.5)](/filings/0001558370-24-015613.md) | [(29.2) d](/filings/0001104659-26-010664.md) | [(64.8)](/filings/0001104659-25-105919.md) | [(43.8)](/filings/0001104659-25-105919.md) | [(36.5)](/filings/0001104659-25-105919.md) | [(48.4) d](/filings/0001104659-26-010664.md) | [(64.1)](/filings/0001104659-26-089450.md) | [(67.8)](/filings/0001104659-26-089450.md) | [(69.4)](/filings/0001104659-25-105919.md) | [(64.7) d](/filings/0001104659-26-010664.md) | [(88.6)](/filings/0001104659-26-089450.md) | [(78.8)](/filings/0001104659-26-089450.md) |
| Diluted EPS | $ per share | [(0.25)](/filings/0001558370-24-015613.md) | not reported | [(0.49)](/filings/0001558370-25-006225.md) | [(0.26)](/filings/0001558370-25-010177.md) | [(0.22)](/filings/0001104659-25-105919.md) | not reported | [(0.38)](/filings/0001104659-26-055256.md) | [(0.39)](/filings/0001104659-26-089450.md) | [(0.38)](/filings/0001104659-25-105919.md) | not reported | [(0.40)](/filings/0001104659-26-055256.md) | [(0.35)](/filings/0001104659-26-089450.md) |
| Basic EPS | $ per share | [(0.01)](/filings/0001558370-24-015613.md) | not reported | [(0.49)](/filings/0001558370-25-006225.md) | [(0.26)](/filings/0001558370-25-010177.md) | [(0.22)](/filings/0001104659-25-105919.md) | not reported | [(0.38)](/filings/0001104659-26-055256.md) | [(0.39)](/filings/0001104659-26-089450.md) | [(0.38)](/filings/0001104659-25-105919.md) | not reported | [(0.40)](/filings/0001104659-26-055256.md) | [(0.35)](/filings/0001104659-26-089450.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [111](/filings/0001558370-24-015613.md) | [196](/filings/0001104659-26-010664.md) | [483](/filings/0001558370-25-006225.md) | [460](/filings/0001558370-25-010177.md) | [427](/filings/0001104659-25-105919.md) | [392](/filings/0001104659-26-010664.md) | [350](/filings/0001104659-26-055256.md) | [391](/filings/0001104659-26-089450.md) | [345](/filings/0001104659-25-105919.md) | [737](/filings/0001104659-26-089450.md) | [667](/filings/0001104659-26-055256.md) | [599](/filings/0001104659-26-089450.md) |
| Current assets | $m | [141](/filings/0001558370-23-017989.md) | [232](/filings/0001558370-25-002000.md) | [520](/filings/0001558370-24-007065.md) | [499](/filings/0001558370-24-011202.md) | [473](/filings/0001558370-24-015613.md) | [441](/filings/0001104659-26-010664.md) | [388](/filings/0001558370-25-006225.md) | [433](/filings/0001558370-25-010177.md) | [387](/filings/0001104659-25-105919.md) | [782](/filings/0001104659-26-089450.md) | [706](/filings/0001104659-26-055256.md) | [644](/filings/0001104659-26-089450.md) |
| Total assets | $m | [162](/filings/0001558370-23-017989.md) | [252](/filings/0001558370-25-002000.md) | [539](/filings/0001558370-24-007065.md) | [517](/filings/0001558370-24-011202.md) | [490](/filings/0001558370-24-015613.md) | [458](/filings/0001104659-26-010664.md) | [406](/filings/0001558370-25-006225.md) | [451](/filings/0001558370-25-010177.md) | [411](/filings/0001104659-25-105919.md) | [808](/filings/0001104659-26-089450.md) | [733](/filings/0001104659-26-055256.md) | [671](/filings/0001104659-26-089450.md) |
| Current liabilities | $m | [35.1](/filings/0001558370-23-017989.md) | [34.9](/filings/0001558370-25-002000.md) | [24.3](/filings/0001558370-24-007065.md) | [30.0](/filings/0001558370-24-011202.md) | [36.4](/filings/0001558370-24-015613.md) | [41.4](/filings/0001104659-26-010664.md) | [37.9](/filings/0001558370-25-006225.md) | [42.9](/filings/0001558370-25-010177.md) | [49.3](/filings/0001104659-25-105919.md) | [50.8](/filings/0001104659-26-089450.md) | [47.7](/filings/0001104659-26-055256.md) | [49.2](/filings/0001104659-26-089450.md) |
| Total liabilities | $m | [155](/filings/0001558370-23-017989.md) | [161](/filings/0001558370-25-002000.md) | [131](/filings/0001558370-24-007065.md) | [139](/filings/0001558370-24-011202.md) | [138](/filings/0001558370-24-015613.md) | [143](/filings/0001104659-26-010664.md) | [140](/filings/0001558370-25-006225.md) | [145](/filings/0001558370-25-010177.md) | [153](/filings/0001104659-25-105919.md) | [154](/filings/0001104659-26-089450.md) | [151](/filings/0001104659-26-055256.md) | [151](/filings/0001104659-26-089450.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [7.9](/filings/0001558370-24-015613.md) | [91.1](/filings/0001104659-26-010664.md) | [408](/filings/0001104659-25-105919.md) | [378](/filings/0001104659-25-105919.md) | [352](/filings/0001104659-25-105919.md) | [315](/filings/0001104659-26-089450.md) | [266](/filings/0001104659-26-089450.md) | [306](/filings/0001104659-26-089450.md) | [258](/filings/0001104659-25-105919.md) | [654](/filings/0001104659-26-089450.md) | [582](/filings/0001104659-26-089450.md) | [520](/filings/0001104659-26-089450.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(7.7) d](/filings/0001558370-24-015613.md) | [(22.5) d](/filings/0001104659-26-010664.md) | [(33.9)](/filings/0001558370-25-006225.md) | [(24.8) d](/filings/0001558370-25-010177.md) | [(36.6) d](/filings/0001104659-25-105919.md) | [(39.4) d](/filings/0001104659-26-010664.md) | [(44.7)](/filings/0001104659-26-055256.md) | [(55.2) d](/filings/0001104659-26-089450.md) | [(50.7) d](/filings/0001104659-25-105919.md) | [(54.2) d](/filings/0001104659-26-010664.md) | [(66.0)](/filings/0001104659-26-055256.md) | [(67.3) d](/filings/0001104659-26-089450.md) |
| Capital expenditure | $m | [0.3 d](/filings/0001558370-24-015613.md) | [0.5 d](/filings/0001104659-26-010664.md) | [0.3](/filings/0001558370-25-006225.md) | [0.7 d](/filings/0001558370-25-010177.md) | [0.1 d](/filings/0001104659-25-105919.md) | [0.2 d](/filings/0001104659-26-010664.md) | [1.9](/filings/0001104659-26-055256.md) | [1.2 d](/filings/0001104659-26-089450.md) | [6.0 d](/filings/0001104659-25-105919.md) | [2.8 d](/filings/0001104659-26-010664.md) | [4.7](/filings/0001104659-26-055256.md) | [3.4 d](/filings/0001104659-26-089450.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [77.0](/filings/0001558370-23-017989.md) | [77.4](/filings/0001558370-24-007065.md) | [78.0](/filings/0001558370-24-011202.md) | [85.1](/filings/0001558370-24-015613.md) | [132](/filings/0001558370-25-006225.md) | [166](/filings/0001558370-25-010177.md) | [167](/filings/0001104659-25-105919.md) | [169](/filings/0001104659-26-055256.md) | [173](/filings/0001104659-26-089450.md) | [184](/filings/0001104659-25-105919.md) | [224](/filings/0001104659-26-055256.md) | [225](/filings/0001104659-26-089450.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 219,615,868 at 2026-07-31, from the cover of the [10-Q filed 2026-08-03](/filings/0001104659-26-089450.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:38 ET. No prices; not investment advice.